842972-42-3

Basic information

• Product Name: 3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE
• Synonyms: CHEMBRDG-BB 4013830;ASINEX-REAG BAS 10152726;AKOS BB-8934;3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE;1-ETHYL-1H-IMIDAZOLE-5-CARBALDEHYDE;1-ethyl-1H-imidazole-5-carbaldehyde hydrochloride;1-ethyl-1H-imidazole-5-carbaldehyde(SALTDATA: FREE)
• CAS NO: 842972-42-3
• Molecular Formula: C6H8N2O
• Molecular Weight: 124.14
• Mol File: 842972-42-3.mol

Chemical Properties

• Boiling Point: 299 °C at 760 mmHg
• Flash Point: 134.6 °C
• Appearance: /
• Density: 1.1 g/cm³
• Vapor Pressure: 0.00123mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE(842972-42-3)
• EPA Substance Registry System: 3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE(842972-42-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 842972-42-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows it to be a versatile component in medicinal chemistry.
Used in Agrochemical Industry:
3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE is used as a precursor in the production of fungicides and pesticides, playing a critical role in the creation of effective crop protection agents that help ensure agricultural productivity and food security.
Used in Fine Chemicals Synthesis:
3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE is used as a building block in the synthesis of fine chemicals, which are important in various applications including fragrances, dyes, and other specialty chemicals.
Used in Research and Development:
3-ETHYL-3H-IMIDAZOLE-4-CARBALDEHYDE is used as a research reagent for studying imidazole-based compounds, which have potential applications in therapeutics and other areas of medicinal chemistry. Its properties make it a valuable tool for scientific exploration and innovation.

InChI:InChI=1/C6H8N2O/c1-2-8-5-7-3-6(8)4-9/h3-5H,2H2,1H3

Upstream product

• 64-67-5 diethyl sulfate 
• 3034-50-2 5-imidazolecarboxaldehyde 
• 3034-50-2 4⁽⁵⁾formylimidazole 

Relevant articles and documents

Synthesis and study of CuII complex with nitroxide, a jumping crystal analog

We synthesized 1-ethylimidazolyl-substituted nitronyl nitroxides, i.e., 2-(1-ethylimidazol-4-yl)- (L4Et) and 2-(1-ethylimidazol-5-yl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazole 3-oxide-1-oxyl (L5Et). The stable radical L5Et is an ethyl analog of 2-(1-methylimidazol-5-yl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazole 3-oxide-1-oxyl (L5Me) described earlier, the reaction of which with Cu(hfac)2 (hfac is 1,1,1,5,5,5-hexafluoropentane-2,4-dionate) leads to the formation of the [Cu(hfac)2(L5Me)2] jumping crystals. The reaction of Cu(hfac)2 with L5Et with reagent ratios 1: 2 and 1: 1 yields heterospin complexes [Cu(hfac)2(L5Et)2] and [Cu(hfac)2L5Et]2, respectively. X-ray diffraction study of the mononuclear complex [Cu(hfac)2(L5Et)2] determined that the compound has a packing similar to that of jumping crystals studied earlier, with the only difference being that the O..O contacts between neigh- boring nitroxide groups were found to be 0.3—0.5 ? longer than in [Cu(hfac)2(L5Me)2]. As a result of the lengthening of these contacts, [Cu(hfac)2(L5Et)2] crystals lack chemomechanical activi- ty. We found that when cooling crystals of binuclear complex [Cu(hfac)2L5Et]2 below 50 K, the antiferromagnetic exchange between unpaired electrons of the >N—?O groups of neighboring molecules leads to the full spin-pairing of the nitroxides, with only the Cu2+ ions contributing to the residual paramagnetism of the compound.

GLP-1R AGONISTS AND USES THEREOF

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.